OWC Pharmaceutical Research Corp (OWCP)

[stockfan100]

OWCP doesn't own any IP? then...these IPs on international patent organizations must look like Christmas ornaments!

Wait!...I see USPTO ornament, Canandian (CA) patent organization ornament, European EPR ornament, IL ornament...oh wait...I see Patent Joke Bar $ Grill (PJBJ) ornament too! But, that one is on "don't buy cause it is free" sale. Is that because PJBJ is a "serious/smart DD" that amounted to nothing after SEC declared S-1 effective?

Count... Patent Family... Filing Domain... Application Published

1....Mlt Myeloma.... IL....12.15.2016
2.... AU.... 12.15.2016
3.... CA.... 12.15.2016
4.... USPTO....05.07.2018
5.... EPR.... 04.18.2018
6.... Mlt Myeloma 2.... IL.... 02.06.2016
7.... EPR.... 04.10.2017
8.... AU.... 02.06.2016
9.... CA.... 02.06.2016
10.... Fibromyalgia.... IL.... 11.17.2016
11.... AU.... 11.17.2016
12 CA.... 11.17.2016
13.... EPR.... 03.21.2018
14.... USPTO....05.03.2018
15.... Pharma Emuls.... IL.... 09.22.2016
16.... EPR.... 01.24.2018
17.... CA.... 09.22.2016
18.... AU.... 09.22.2016
19.... USPTO....02.15.2018
20.... Migraine..... IL.... 06.16.2016
21.... Sexual Func.... IL.... 06.23.2016
22.... USPTO.... 12.28.2017
23.... EPR.... 06.23.2016
24.... Skin Disord.... IL....06.30.2016
26.... AU.... 06.30.2016
26.... USPTO.... 02.15.2018

*The Psoriasis agreement with Sheba Academic Medical Center provides that all intellectual property that is conceived during the course of the research is to be jointly owned by Sheba and One World Cannabis.


Multiple Myeloma

Abstract

The present invention discloses a cytotoxic cocktail comprising;(a) a therapeutically effective amount of at least one cannabinoid selected from the group consisting of; cannobidiol (CBD) or a derivative thereof, Tetrahydrocannabinol (THC) or a derivative thereof, an any combination thereof nf (b) at least one therapeutic agent selected from the group consisting of: bortezomib (BTZ), carfilzomib (CFZ), lenalidomide (LEN), dexamethasone (DEX), melphalan (MEL) and doxorubicin (DOXO). In a core embodiment the cocktail is conferring a synergistic effect with respect to inhibition or cytotoxicity of multiple myeloma (MM) cells, relative to said at least one therapeutic agent selected from the group consisting of: BZ, CFZ, DEX, MEL, DOXO and said CBD and THC, administered separately in similar concentration.

Novel cannabinoid combination therapies for multiple myeloma (mm) (23 pages)
https://www.freshpatents.com/-dt20180705ptan20180185324.php


Fibromyalgia

Abstract

The present invention discloses a composition comprising cannabis natural extract, or synthesis cannabinoids, for use in treating a subject suffering from fibromyalgia. The present invention further discloses methods and uses of the aforementioned composition.

Use of cannabis to treat fibromyalgia, methods and compositions thereof (19 pages)
https://www.freshpatents.com/-dt20180503ptan20180116998.php


Skin Disorders

Abstract

The present invention discloses a pharmaceutical topical composition comprising cannabidiol (CBD) or a derivative thereof and Tetrahydrocannabinol (THC) or a derivative thereof in an about 1:1 ratio, useful for treatment or prevention of inflammatory skin disorders, and treatment methods thereof.

Cannabis-based extracts and topical formulations for use in skin disorders(31 pages)

https://www.freshpatents.com/-dt20180215ptan20180042890.php